advertisement
Abstract #46885 Published in IGR 13-3
Real-life experience study of the safety and efficacy of travoprost 0.004% / timoptol 0.50% fixed combination ophthalmic solution in intraocular pressure control
Olali C; Malietzis G; Ahmed S; Samaila E; Gupta MNigerian journal of clinical practice 2011; 14: 29-33
Purpose: To evaluate the safety and efficacy of timolol 0.5%/travoprost 0.004% combination (duotrav) as observed in primary open-angle glaucoma (POAG), ocular hypertension (OHT) and normal tension glaucoma (NTG) in real-life conditions. Materials and Methods: Patients with uncontrolled intraocular pressure (IOP) on other medication and no contraindication to p-blockers were switched to duotrav in 56 eyes of 28 patients. The drop in IOP was the primary outcome measured. Results: Switch to duotrav provided an additional IOP reduction after 3-month follow-up that was statistically significant for those on latanoprost (P=O. 02857), bimatoprost (P =0.04978) and travoprost (P =0.0078). Patients on latanotrost had an additional 25.9% drop 3 months after switching to duotrav while those on bimatoprost and travatan had 18.04% and 17.59% drop, respectively, after the switch. It was effective in lowering the IOP to clinically significant levels of (less-than or equal to)18.5 mmHg in POAG, NTG and OHT (12.5-17.9% drop), but not in chronic angle closure glaucoma. Conclusion: Duotrav was well-tolerated and produced significant additional IOP reduction when switched from other anti-glaucoma drugs in patients with uncontrolled glaucoma. It also achieved IOP of (less-than or equal to)18.5 mmHg in glaucoma patients.
C. Olali. Department of Royle Eye, Pilgrim Hospital, Boston, Lincolnshire, United Kingdom.
Classification:
11.13.4 Betablocker and prostaglandin (Part of: 11 Medical treatment > 11.13 Combination therapy)
